Resolution Therapeutics Announces £63.5 Million Series B …

Oct 3, 2024 · The proceeds from the Series B financing will be used to advance Resolution's lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy …

CouponFollow Extension

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024 · The proceeds from the Series B financing will be used to advance Resolution's lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy …

prnewswire.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Mar 10, 2024 · The proceeds from the Series B financing will be used to advance Resolution’s lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell …

synconaltd.com

£63
OFF

Resolution Therapeutics Raises £63.5 Million In Series B Financing …

6 days from now

Oct 3, 2024 · Based on the strength of this data, Resolution is now focused on advancing its lead candidate, RTX001, an enhanced, next-generation macrophage cell therapy with first-in-class …

pharmiweb.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024 · The proceeds from the Series B financing will be used to advance Resolution’s lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy …

resolution-tx.com

$83
OFF

Resolution Therapeutics Raises £63.5M In Series B Funding

6 days from now

Oct 3, 2024 · NEW YORK – Resolution Therapeutics on Thursday said it has raised £63.5 million ($83.3 million) in Series B financing led by Syncona.

precisionmedicineonline.com

£63
OFF

Resolution Therapeutics Raises £63.5M In Series B Financing

6 days from now

Oct 3, 2024 · Resolution Therapeutics, an Edinburgh, Scotland, and London, UK-based clinical-stage biopharmaceutical company, raised £63.5M in Series B funding.

finsmes.com

£63
OFF

Edinburgh’s Resolution Therapeutics Raises £63m

6 days from now

Oct 3, 2024 · Edinburgh-based Resolution Therapeutics Limited announced it has raised £63.5 million in Series B financing round led by investment firm Syncona Ltd. Resolution is a clinical …

scottishfinancialreview.com

£63
OFF

Syncona Commits £63.5m To Resolution Therapies

6 days from now

Oct 3, 2024 · Syncona announced on Thursday that it has committed £63.5m in series B financing to Resolution Therapeutics, a portfolio company focused on macrophage therapy for …

sharecast.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024 · EDINBURGH, Scotland and LONDON, Oct. 3, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on …

epicos.com

$85
OFF

Resolution Therapeutics' Macrophage Therapy Raises $85 Million

6 days from now

Oct 3, 2024 · Today, Resolution Therapeutics, a clinical-stage biotech company, secured $85 million (£63.5 million) in series B financing to advance its lead product candidate, RTX001, into …

labiotech.eu

£63
OFF

Syncona Ploughs £63.5m Into Resolution Therapeutics

6 days from now

Oct 3, 2024 · The Series B financing brings the total amount raised by Resolution to £101.4m. Following the drawdown of the full Series B financing, Syncona’s ownership stake in …

theaic.co.uk

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 4, 2024 · Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the …

pharmajournalist.com

£63
OFF

Resolution Therapeutics And CCRM Sign Collaboration Agreement …

6 days from now

Nov 7, 2022 · Resolution Therapeutics and CCRM announce the signing of a collaboration in iPSC-derived macrophage cell therapies. ... Resolution Therapeutics Announces £63.5 Million …

resolution-tx.com

$83
OFF

Resolution Therapeutics Secures $83M To Advance Liver Therapy

6 days from now

Oct 3, 2024 · Resolution announced this week that it had raised £63.5 million (US$ 83 million) in Series B financing. The round adds to an earlier £26.6 million (US$ 35 million) Series A …

biopharma-reporter.com

£63
OFF

Resolution Therapeutics Raises £63.5m In Series B Financing

6 days from now

Oct 31, 2024 · Resolution Therapeutics has raised £63.5 million in Series B financing, led by Syncona.

healthinvestor.co.uk

FAQs about Resolution Therapeutics Announces £63.5 Million Series B … Coupon?

How much did resolution raise in Series B financing?

Resolution announced this week that it had raised £63.5 million (US$ 83 million) in Series B financing. The round adds to an earlier £26.6 million (US$ 35 million) Series A financing in 2020. ...

Is resolution a regenerative biopharmaceutical company?

EDINBURGH, Scotland and LONDON, Oct. 3, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases, today announces it has raised £63.5 million in Series B financing. ...

What is resolution Therapeutics?

About Resolution Therapeutics Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases. ...

Who financed rtx001?

Both financing round were led by Syncona, which has a range of biotech companies in its portfolio including Autolus Therapeutics, Beacon Therapeutics, iOnctura, Anaveon, and Purespring Therapeutics, among others. Resolution plans to use the new financing to progress RTX001, its lead candidate, into clinical trials. ...

Will rtx001 go into clinical trials?

Resolution plans to use the new financing to progress RTX001, its lead candidate, into clinical trials. RTX001 is an engineered autologous macrophage cell therapy for treatment of end stage liver disease. ...

Who is omniabio & resolution Therapeutics?

OmniaBio has the expertise, infrastructure and a strong focus on cell and gene therapies to deliver impact on this project and eventually to patients.” Resolution Therapeutics is a biotechnology company developing macrophage cell therapies to treat advanced liver disease. ...